TCGA-AO-A1KQ-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- ESTROGEN_RESPONSE_LATE+0.360
- INTERFERON_ALPHA_RESPONSE+0.350
- MYC_TARGETS_V1+0.330
- MYC_TARGETS_V2+0.310
- ALLOGRAFT_REJECTION+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- INTERFERON_GAMMA_RESPONSE+0.280
- SPERMATOGENESIS+0.270
- MTORC1_SIGNALING+0.260
Top 10 suppressed
- UV_RESPONSE_DN-0.440
- HEDGEHOG_SIGNALING-0.410
- TGF_BETA_SIGNALING-0.360
- MITOTIC_SPINDLE-0.350
- ANDROGEN_RESPONSE-0.330
- APICAL_JUNCTION-0.300
- PROTEIN_SECRETION-0.300
- WNT_BETA_CATENIN_SIGNALING-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- HEME_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.857 |
| 2 | C3N-03486 | — | cohortSQ1 | 0.821 |
| 3 | TCGA-22-5471-01A-01R-1635-07 | — | cohortSQ2 | 0.817 |
| 4 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.815 |
| 5 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.815 |
| 6 | TCGA-64-1677-01A-01R-0946-07 | — | cohortA1 | 0.778 |
| 7 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.777 |
| 8 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.766 |
| 9 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.761 |
| 10 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |